Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Potentially Resectable Hepatocellular Carcinoma”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Testing effectiveness (Phase 2)Temporarily pausedNCT06405061
What this trial is testing

Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma

Who this might be right for
AdebrelimabHepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 40
Testing effectiveness (Phase 2)UnknownNCT04241523
What this trial is testing

Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC

Who this might be right for
Hepatocellular Carcinoma (HCC)
Shanghai Zhongshan Hospital 50
Not applicableUnknownNCT03591705
What this trial is testing

TACE-HAIC vs. HAIC for Potentially Resectable HCC

Who this might be right for
Potentially ResectionHepatocellular Carcinoma
Sun Yat-sen University 240
Testing effectiveness (Phase 2)UnknownNCT04843943
What this trial is testing

Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

Who this might be right for
Hepatocellular Carcinoma
Fudan University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03869034
What this trial is testing

HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC

Who this might be right for
Hepatocellular Carcinoma
Sun Yat-sen University 40
Testing effectiveness (Phase 2)Looking for participantsNCT07012798
What this trial is testing

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma (HCC)
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)UnknownNCT04850040
What this trial is testing

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Who this might be right for
Hepatocellular Carcinoma Resectable
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 15
Testing effectiveness (Phase 2)Looking for participantsNCT07801287
What this trial is testing

Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC

Who this might be right for
HCC - Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 20
Large-scale testing (Phase 3)Looking for participantsNCT06796803
What this trial is testing

Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

Who this might be right for
Potentially Resectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 398
Not applicableNot Yet RecruitingNCT07738055
What this trial is testing

Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC Conversion

Who this might be right for
Potentially Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 35
Not applicableLooking for participantsNCT07070076
What this trial is testing

A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma (HCC)
Li Qiang 286
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07119931
What this trial is testing

A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)

Who this might be right for
HCC
Tianjin Medical University Cancer Institute and Hospital 34
Testing effectiveness (Phase 2)UnknownNCT05864755
What this trial is testing

HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Who this might be right for
Unrescetable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06143579
What this trial is testing

HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma

Who this might be right for
Potentially Resectable Hepatocellular Carcinoma
Sun Yat-sen University 48
Early research (Phase 1)Active Not RecruitingNCT04658147
What this trial is testing

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Who this might be right for
Hepatocellular Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 31
Large-scale testing (Phase 3)UnknownNCT05056337
What this trial is testing

Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 220
Large-scale testing (Phase 3)Looking for participantsNCT06041477
What this trial is testing

Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC

Who this might be right for
Hepatocellular CarcinomaChemotherapy EffectChemotherapeutic Toxicity
Sun Yat-sen University 540
Not applicableLooking for participantsNCT05994859
What this trial is testing

SIRT for Potentially Resectable HCC

Who this might be right for
Hepatocellular Carcinoma
Second Affiliated Hospital of Guangzhou Medical University 35